🔍

MEDANTA - Global Health

📊 NSE: MEDANTA 🏢 Healthcare 📅 Last Updated: 12/13/2025 22:23

📢 Recent Corporate Announcements

Medanta Shareholders Approve Key Director Appointments with Over 99% Majority

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 14 Mar 2026, 05:28 PM

Global Health Limited (Medanta) has successfully passed three resolutions via postal ballot with overwhelming shareholder support. Dr. Ravi Gupta and Mr. Rajan Bharti Mittal were re-appointed as Independent Directors, receiving 99.64% and 99.65% of votes in favor, respectively. Furthermore, Ms. Shonan Purie Trehan was appointed as a Non-Executive Non-Independent Director with 99.82% approval. The high participation and near-unanimous voting from institutional and public shareholders reflect strong confidence in the company's governance.

Resolution for Dr. Ravi Gupta's re-appointment passed with 99.6383% votes in favor.
Mr. Rajan Bharti Mittal's re-appointment as Independent Director secured 99.6517% approval.
Appointment of Ms. Shonan Purie Trehan as Non-Executive Director passed with 99.8236% support.
Total valid votes cast amounted to 24,12,94,677, representing high shareholder engagement across promoter and public categories.

💡 The overwhelming support for these appointments indicates strong institutional trust in Medanta's leadership. Investors can remain confident in the company's stable governance and continuity of its strategic direction.

Medanta Schedules One-on-One Investor Meeting with HSBC Securities on March 17

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Mar 2026, 06:13 PM

Global Health Limited (Medanta) has announced a one-on-one meeting with HSBC Securities and Capital Markets (India) Private Limited. The meeting is scheduled for March 17, 2026, and will be conducted in person at Noida. This is a routine regulatory filing under SEBI (LODR) Regulations, 2015. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the session.

One-on-one meeting scheduled with HSBC Securities on March 17, 2026.
The meeting will be held in person at Noida.
Compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
Company confirms no unpublished price sensitive information (UPSI) will be shared.

💡 No immediate action is required as this is a standard institutional interaction. Investors may look for any subsequent investor presentations that might be uploaded to the exchanges.

Medanta to Meet Institutional Investors in Gurugram on March 16, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Mar 2026, 07:10 PM

Global Health Limited (Medanta) has announced a group meeting with institutional investors and analysts scheduled for March 16, 2026. The meeting is being organized by Goldman Sachs and will be held in person at Gurugram. The company has explicitly stated that no unpublished price-sensitive information (UPSI) will be shared during this interaction. This event is part of Medanta's routine investor relations activities to maintain transparency with the financial community.

Group meeting with analysts and institutional investors scheduled for March 16, 2026.
The meeting is organized by Goldman Sachs and will be conducted in person in Gurugram.
Compliance disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed.

💡 No immediate action is required as this is a routine corporate disclosure. Investors should watch for any investor presentations or transcripts that may be released following the meeting for insights into the company's growth strategy.

Medanta Schedules One-on-One Investor Meeting for February 27, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 19 Feb 2026, 05:48 PM

Global Health Limited (Medanta) has announced a one-on-one meeting with institutional investors scheduled for February 27, 2026. The meeting will be held in person at Gurugram and is being organized by BofA Securities India Limited. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during this interaction. This is a standard regulatory disclosure in compliance with SEBI (LODR) Regulations, 2015.

One-on-one meeting with institutional investors scheduled for February 27, 2026.
The meeting is organized by BofA Securities India Limited.
Interaction will take place in person in Gurugram.
Company confirms that no unpublished price sensitive information will be shared.

💡 This is a routine investor relations update and requires no immediate action. Investors may monitor the company's website for any post-meeting presentations or transcripts if they become available.

Medanta Schedules Institutional Investor Meetings from February 24 to 26, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 17 Feb 2026, 06:06 PM

Global Health Limited (Medanta) has announced a series of upcoming interactions with institutional investors and analysts. The management will participate in the Kotak India Conference on February 24 and IIFL's 17th Enterprising India Global Investors' Conference on February 25, both in Mumbai. Additionally, a group meeting with Kotak Securities is scheduled for February 26 in Gurugram. These meetings are intended to discuss the company's growth trajectory and business outlook in one-to-one and group formats.

Participation in Kotak India Conference: Chasing Growth 2026 on February 24 in Mumbai.
Attendance at IIFL's 17th Enterprising India Global Investors' Conference on February 25 in Mumbai.
Scheduled group meeting with Kotak Securities on February 26 in Gurugram.
Meetings will be conducted in person and include both one-to-one and group interaction modes.
Company confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared during these meets.

💡 No immediate action is required as this is a routine corporate disclosure. Investors should watch for any investor presentations or management transcripts that may be released following these conferences.

Medanta Seeks Approval for Re-appointment of 2 Independent Directors and 1 New Board Member

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 10 Feb 2026, 01:12 PM

Global Health Limited (Medanta) has issued a postal ballot notice to seek shareholder approval for key board appointments. The company proposes the re-appointment of Dr. Ravi Gupta and Mr. Rajan Bharti Mittal as Independent Directors for a second five-year term starting July 2026. Additionally, Ms. Shonan Purie Trehan is proposed for appointment as a Non-Executive Non-Independent Director. The e-voting process is scheduled from February 12 to March 13, 2026, for shareholders holding stock as of the February 6, 2026 cut-off date.

Proposed re-appointment of Dr. Ravi Gupta as Independent Director for a 5-year term starting July 8, 2026
Proposed re-appointment of Mr. Rajan Bharti Mittal as Independent Director for a 5-year term starting July 8, 2026
Appointment of Ms. Shonan Purie Trehan as a Non-Executive Non-Independent Director
E-voting period set from February 12, 2026, to March 13, 2026
Independent Director commissions collectively capped at 1% of the company's annual net profits

💡 Shareholders should review the proposed appointments and participate in the e-voting process to exercise their governance rights. The re-appointments indicate a focus on maintaining board continuity and stability.

Medanta Q3 FY26: Revenue Grows 19% to Rs 1,143 Cr; Noida Ramp-up Impacts Margins

🔵 WATCH ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 06:27 PM

Global Health Limited (Medanta) reported a robust 19% YoY revenue growth to Rs 11,428 million for Q3 FY26, driven by strong performance across its hospital network. While core EBITDA margins (excluding Noida) remained healthy at 25.4%, consolidated margins were pressured to 21.8% due to a Rs 320 million operating loss from the newly commissioned Noida facility. Reported PAT of Rs 950 million was impacted by a one-time exceptional labor code charge of Rs 366 million, though adjusted PAT stood higher at Rs 1,224 million. Operational metrics remained strong with ARPOB increasing 10% YoY to Rs 67,361.

Total income rose 19% YoY to Rs 11,428 million; Adjusted PAT stood at Rs 1,224 million excluding one-time items.
ARPOB increased by 10% YoY to Rs 67,361, while Average Length of Stay (ALOS) improved by 7% to 3.02 days.
International patient revenue grew significantly by 30% YoY to Rs 703 million.
Noida facility completed its first full quarter with Rs 343 million revenue and expanded to 328 beds.
Developing hospitals (Lucknow and Patna) delivered 22% revenue growth with strong EBITDA margins of 31.7%.

💡 Investors should focus on the pace of the Noida facility's EBITDA breakeven and the execution of the 496-bed brownfield expansion pipeline. The stock remains a solid play on premium healthcare, but short-term margins will be influenced by the gestation period of new units.

Medanta Releases Q3 FY26 Earnings Conference Call Audio Recording

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 05 Feb 2026, 04:50 PM

Global Health Limited (Medanta) has officially released the audio recording of its earnings conference call for the third quarter and nine-month period ended December 31, 2025. The call, hosted by JM Financial, took place on February 5, 2026, following the announcement of the company's financial results. This disclosure is a routine regulatory requirement under SEBI's Listing Obligations and Disclosure Requirements. Investors can now access the full discussion regarding the company's operational performance and management outlook via the provided link on the company's website.

Earnings conference call conducted on February 5, 2026, at 2:00 P.M. IST.
Covers financial and operational performance for Q3 and 9M ended December 31, 2025.
The session was hosted by JM Financial for institutional investors and analysts.
Audio recording link is now publicly available on the Medanta investor relations portal for transparency.

💡 Investors should listen to the recording to gain insights into management's commentary on occupancy rates, ARPOB trends, and the progress of new hospital projects. This information is crucial for evaluating the company's growth sustainability and margin profile.

Medanta Q3 FY26: Revenue Grows 19% to ₹1,143 Cr; PAT Impacted by Noida Launch and Labour Code Costs

🔵 WATCH ⭐ 8/10

EARNINGS 📅 04 Feb 2026, 06:26 PM

Global Health (Medanta) reported a strong 19.1% y-o-y revenue growth for Q3 FY26, reaching INR 11,428 million, driven by robust patient volumes and a 9.9% increase in ARPOB. However, reported PAT declined 33.5% y-o-y to INR 950 million, primarily due to initial operating losses and depreciation from the new Noida facility, alongside a one-time exceptional charge of INR 366 million for new Labour Code compliance. Excluding the Noida unit, EBITDA grew by 10.9%, demonstrating healthy core performance across matured and developing hospitals. The company continues its aggressive expansion, adding 144 beds during the quarter and planning a new 750-bed facility in Delhi.

Total Income rose 19.1% y-o-y to INR 11,428 million, supported by a 14.3% growth in In-patient volumes.
ARPOB increased 9.9% y-o-y to INR 67,361, while Average Length of Stay (ALOS) improved by 6.6% to 3.02 days.
The newly launched Noida hospital reported a revenue of INR 343 million but incurred an EBITDA loss of INR 320 million.
A non-recurring exceptional item of INR 366 million was recorded due to the statutory impact of new Labour Codes.
International patient revenue grew significantly by 29.9% y-o-y, reaching INR 703 million.

💡 Investors should look past the temporary PAT decline caused by one-off costs and the Noida scale-up phase, focusing instead on the strong 19% top-line growth and improving operational metrics. Monitor the Noida facility's path to EBITDA break-even as a key catalyst for margin recovery in upcoming quarters.

Medanta Q3 FY26: Total Income up 19% to INR 11,428 Mn; PAT hit by Noida launch & one-time costs

🔵 WATCH ⭐ 8/10

EARNINGS 📅 04 Feb 2026, 06:24 PM

Global Health (Medanta) reported a 19.1% YoY increase in total income to INR 11,428 million for Q3 FY26, driven by strong volume growth and higher realizations. Consolidated PAT declined 33.5% YoY to INR 950 million, significantly impacted by a non-recurring exceptional item of INR 366 million related to new Labour Codes and initial losses from the Noida facility. Operational efficiency improved with ARPOB rising 9.9% to INR 67,361 and inpatient counts up 14.3%. The new Noida hospital is scaling up, contributing INR 343 million in revenue while still in its gestation phase.

Total Income rose 19.1% YoY to INR 11,428 million; 9M FY26 income up 17.6% to INR 33,131 million.
ARPOB grew 9.9% YoY to INR 67,361, while In-patient and Out-patient counts rose 14.3% and 19.5% respectively.
PAT fell 33.5% YoY to INR 950 million due to a INR 366 million exceptional labor code charge and Noida startup costs.
Medanta Noida reported its first full quarter with INR 343 million revenue and an EBITDA loss of INR 320 million.
Developing hospitals (ex-Noida) showed strong performance with 21.5% revenue growth and 31.7% EBITDA margins.

💡 Investors should focus on the robust top-line growth and operational metrics like ARPOB, as the PAT decline is largely due to non-recurring items and planned expansion gestation. Monitor the ramp-up and EBITDA breakeven timeline of the Noida facility.

Medanta Q3 Revenue Up 15.7% YoY to ₹9,402 Mn; PAT Impacted by ₹352 Mn Exceptional Charge

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 04 Feb 2026, 04:20 PM

Global Health Limited (Medanta) reported a 15.7% YoY increase in revenue from operations to ₹9,401.65 million for Q3 FY26. However, Profit After Tax (PAT) declined to ₹799.07 million from ₹1,313.86 million in the previous year's restated quarter, primarily due to a ₹352 million exceptional charge related to new Labour Codes. The company also announced management changes, including the appointment of Malik Mohd. Ashhab as Head of Diagnostic Services. While top-line growth remains healthy, operational expenses, particularly employee benefits and consultant fees, saw a notable increase during the period.

Revenue from operations grew 15.7% YoY to ₹9,401.65 million in Q3 FY26 compared to ₹8,123.67 million in Q3 FY25.
Profit After Tax (PAT) stood at ₹799.07 million, significantly impacted by a ₹352 million exceptional item for Labour Code compliance.
Employee benefit expenses rose 36% YoY to ₹2,523 million, reflecting increased staffing and potential wage adjustments.
Malik Mohd. Ashhab appointed as Head-Diagnostic Services to strengthen the senior management team.
Board recommended the re-appointment of Independent Directors Dr. Ravi Gupta and Mr. Rajan Bharti Mittal for second 5-year terms.

💡 Investors should look through the one-time exceptional hit to PAT and focus on the robust 15%+ revenue growth. It is important to monitor if the rising employee and consultancy costs are structural or temporary to assess long-term margin stability.

Medanta Q3 Revenue Rises 15.7% to ₹9,402 Mn; PAT Impacted by Exceptional Labour Code Costs

🔵 WATCH ⭐ 8/10

EARNINGS 📅 04 Feb 2026, 04:16 PM

Global Health Limited (Medanta) reported a steady 15.7% YoY revenue growth for Q3 FY26, reaching ₹9,401.65 million. However, Net Profit (PAT) for the quarter declined to ₹799.07 million from ₹1,313.86 million (restated) in the previous year, primarily due to a one-time exceptional charge of ₹352 million related to new Labour Codes. On a nine-month basis, the company remains profitable with a PAT of ₹3,720.70 million. The board also strengthened leadership by appointing a new Head of Diagnostic Services and re-appointing two key Independent Directors.

Revenue from operations grew 15.7% YoY to ₹9,401.65 million in Q3 FY26 compared to ₹8,123.67 million (restated) in Q3 FY25.
Profit After Tax (PAT) stood at ₹799.07 million, significantly impacted by a ₹352 million exceptional expense for Labour Code provisions.
Nine-month (9M FY26) revenue reached ₹27,487.49 million, showing healthy growth over the ₹24,012.78 million recorded in the same period last year.
Mr. Malik Mohd. Ashhab appointed as Head-Diagnostic Services to lead the company's diagnostic segment expansion.
Dr. Ravi Gupta and Mr. Rajan Bharti Mittal re-appointed as Independent Directors for a second 5-year term starting July 2026.

💡 Investors should focus on the robust double-digit revenue growth while treating the PAT decline as a largely one-time accounting adjustment due to labour code provisions. Monitor the performance of the diagnostic services segment under new leadership for future margin improvements.

Medanta Q3 Revenue Up 15.7% YoY to ₹9,402 Mn; PAT Declines on Exceptional Costs

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 04 Feb 2026, 03:37 PM

Global Health Limited (Medanta) reported a steady 15.7% YoY growth in standalone revenue for Q3 FY26, reaching ₹9,401.65 million. However, Profit After Tax (PAT) saw a significant decline to ₹799.07 million from ₹1,313.86 million in the year-ago period (restated). This profitability hit was largely due to a ₹352 million exceptional expense related to new Labour Codes and a sharp rise in employee benefit expenses and consultancy fees. The company also strengthened its leadership by appointing a new Head of Diagnostic Services.

Revenue from operations increased 15.7% YoY to ₹9,401.65 million from ₹8,123.67 million.
Standalone Profit After Tax (PAT) dropped 39% YoY to ₹799.07 million.
Exceptional item of ₹352 million recognized in Q3 FY26 due to the impact of new Labour Codes.
Employee benefit expenses rose significantly to ₹2,523 million compared to ₹1,850 million in Q3 FY25.
Appointment of Mr. Malik Mohd. Ashhab as Head-Diagnostic Services to lead the diagnostics vertical.

💡 Investors should be cautious as rising operating costs (employee and consultancy fees) are currently compressing margins despite healthy revenue growth. Monitor management's commentary on whether the Labour Code impact is a one-time hit or will lead to sustained higher personnel costs.

Medanta (Global Health) Grants 4,000 ESOPs to Employee at Rs 2 Exercise Price

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 03 Feb 2026, 03:26 PM

Global Health Limited (Medanta) has approved the grant of 4,000 stock options to a single employee under its Employee Long Term Share Based Incentive Plan 2024. The exercise price for these options is set at Rs 2 per share, which is the face value of the stock. The vesting period for these options can extend up to five years, with an exercise window of three years from the final vesting date. This is a routine administrative action aimed at talent retention and involves a negligible number of shares.

Grant of 4,000 stock options to one employee under the GHL LTIP 2024 Plan
Exercise price fixed at Rs 2 per share, significantly below current market price
Vesting period spans up to a maximum of 5 years from the date of grant
Each option is convertible into one equity share of face value Rs 2

💡 No action is required as the grant size is insignificant and will not cause any material dilution to existing shareholders. Investors should continue to monitor the company's core hospital operations and expansion metrics.

Medanta (Global Health) Reports Nil Demat/Remat Requests for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Jan 2026, 05:47 PM

Global Health Limited (Medanta) has submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2025. The company's Registrar and Transfer Agent, KFin Technologies Limited, confirmed that no securities were dematerialized or rematerialized during this period. This is a standard quarterly regulatory filing intended to confirm the status of share conversion requests. As there were zero requests, no further updates to the depositories or stock exchanges were necessary.

Compliance certificate issued for the quarter ended December 31, 2025.
Registrar KFin Technologies confirmed Nil securities were dematerialized or rematerialized.
The filing adheres to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
No changes were made to the share registry regarding physical-to-electronic conversions during the quarter.

💡 This is a routine administrative filing with no impact on the company's fundamentals or stock performance. No action is required from investors.

View All MEDANTA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Matured hospitals (Gurugram, Indore, Ranchi) grew 10.6% YoY to INR 26,119 million in FY25; Developing hospitals (Lucknow, Patna) grew 10% YoY to INR 10,940 million. Outpatient pharmacy revenue increased 26% from INR 1,120 million to INR 1,400 million. International patient revenue grew 7.8% in FY25 and surged 49% YoY in Q2 FY26 to INR 762 million.

Geographic Revenue Split

Revenue is diversified across 5 states. Matured facilities (Gurugram, Indore, Ranchi) contribute approximately 70.5% of healthcare services revenue, while developing facilities (Lucknow, Patna) contribute 29.5%. International patients account for approximately 5.5% of total revenue in FY25.

Profitability Margins

Consolidated PAT margin was 12.8% in FY25. In Q2 FY26, PAT margin improved to 14.2% from 13.4% YoY. Standalone profitability declined 5.1% due to one-time merger provisioning, while consolidated PAT grew 0.68% in FY25 to INR 4,813.18 million.

EBITDA Margin

Consolidated EBITDA margin was 25.4% in FY25 (INR 9,561.6 million), down from 26.1% YoY. Q2 FY26 EBITDA margin (ex-Noida) was 25.2%, while including Noida startup losses, the margin was 23.3% (INR 2,607 million).

Capital Expenditure

H1 FY26 capex was INR 4,252 million. Total planned project capex is estimated at INR 36,700 million for 2,000 additional beds. Maintenance capex is projected at INR 4,500 million over the next three years. The Noida project cost was revised upward to INR 15,300 million to accommodate 750 beds.

Credit Rating & Borrowing

CRISIL A+/Positive rating for major subsidiaries. Interest coverage ratio improved to 10.5 times in fiscal 2024 from 7.83 times. Debt-to-Equity ratio improved to 0.10x in FY25 from 0.14x following debt repayment.

⚙️ Operational Drivers

Raw Materials

Medical consumables, pharmaceuticals, and surgical implants represent the primary variable costs, though specific % of total cost is not disclosed. Employee benefits (doctors/nurses) are a major cost driver with 11,800+ staff.

Import Sources

Not specifically disclosed, but medical equipment like the 128-slice Dual Source CT and MAGNETOM Altea 1.5 Tesla MRI are sourced from global medical technology providers.

Key Suppliers

Partnerships include US-based firms for DOCBOX cardiac monitoring and Qure.ai for AI-powered imaging decision support.

Capacity Expansion

Current capacity includes 57 new beds added at Patna in H1 FY26. Planned expansion of 1,000 beds across Noida, Lucknow, Patna, and Ranchi, plus 2,000 beds via greenfield projects in Mumbai (Oshiwara), Pitampura (Delhi), and Guwahati (Assam) over 3-4 years.

Raw Material Costs

Inventory turnover improved to 13.13x in FY25 from 11.94x, indicating more efficient management of medical supplies and pharmacy stock.

Manufacturing Efficiency

Occupancy stood at ~64% in Q2 FY26 on increased bed capacity. ARPOB (Average Revenue Per Occupied Bed) grew 5.5% YoY to INR 65,570, reflecting better case mix and realization.

Logistics & Distribution

Not disclosed as a % of revenue; however, the company operates hospital-based and retail outpatient pharmacies which grew 26% in revenue.

📈 Strategic Growth

Expected Growth Rate

15%

Growth Strategy

Growth will be driven by adding 2,000 beds through greenfield projects in Mumbai, Delhi, and Guwahati, and scaling the 750-bed Noida facility. The company is also increasing its international patient reach (49% growth in Q2 FY26) and expanding its outpatient pharmacy and digital health (AI/predictive analytics) offerings.

Products & Services

Tertiary and quaternary healthcare services specializing in Cardiac Sciences, Oncology, Gastroenterology, Neurosciences, and Renal Sciences/Urology, which contribute 65.8% of revenue.

Brand Portfolio

Medanta, Global Health Limited, Medanta The Medicity.

New Products/Services

Launch of Medanta Noida in September 2025 (INR 39 million revenue in month one). New AI-powered services like DOCBOX and Qure.ai imaging support are expected to enhance clinical outcomes.

Market Expansion

Expansion into Mumbai (Oshiwara), Pitampura (Delhi), and Guwahati (Assam) with large-format greenfield hospitals over the next 3-4 years.

Market Share & Ranking

Not specifically ranked by %, but described as a 'trusted leader' and 'destination for high-end tertiary care' in North and East India.

Strategic Alliances

Collaborations with the UP state government for 'Mission TB-Free' and partnerships with US-based firms for cardiac critical care monitoring systems.

🌍 External Factors

Industry Trends

The industry is shifting toward digital health and AI integration. Medanta is positioning itself by adopting AI-powered imaging and next-gen cardiac monitoring to maintain its 'destination care' status.

Competitive Landscape

Faces competition from other private hospital chains in metro areas, which risks talent poaching and pressure on occupancy rates.

Competitive Moat

Moat is built on 'Clinical Excellence' and a 'Doctor-led' model. The brand reputation for complex quaternary care (65.8% revenue from top 5 specialties) and high-end infrastructure makes it difficult for new entrants to replicate.

Macro Economic Sensitivity

Highly sensitive to healthcare spending trends and insurance penetration. Growing demand for high-quality healthcare in underserved regions like Patna and Lucknow drives the 10% growth in developing hospitals.

Consumer Behavior

Shift toward seeking 'destination care' for complex surgeries, benefiting Medanta's high-end tertiary model.

Geopolitical Risks

Medical value travel (international patients) is subject to geopolitical stability and visa regulations, impacting the 5.5% revenue share from this segment.

⚖️ Regulatory & Governance

Industry Regulations

Compliance with the Companies Act 2013, SEBI Listing Regulations, and healthcare-specific standards for clinical excellence and patient safety.

Environmental Compliance

ESG oversight is managed by the Board; initiatives include the 'TB-Free Uttar Pradesh' campaign and early breast cancer detection programs.

Taxation Policy Impact

Effective tax rate resulted in tax expenses of INR 1,659.39 million on PBT of INR 6,472.57 million (approx 25.6%) in FY25.

Legal Contingencies

The company monitors brand equity risks related to legal non-compliance or patient dissatisfaction; specific pending case values are not disclosed in the provided text.

⚠️ Risk Analysis

Key Uncertainties

Expansion risk: Delays in constructing the 2,000-bed pipeline could impact projected returns. People risk: High turnover of skilled professionals could damage brand reputation.